LA-EP2006 + Neulasta®
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenic Complications
Conditions
Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
Trial Timeline
Jun 1, 2012 → Feb 1, 2014
NCT ID
NCT01735175About LA-EP2006 + Neulasta®
LA-EP2006 + Neulasta® is a phase 3 stage product being developed by Sandoz Group for Neutropenic Complications. The current trial status is completed. This product is registered under clinical trial identifier NCT01735175. Target conditions include Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia.
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01735175 | Phase 3 | Completed |
| NCT01516736 | Phase 3 | Completed |